Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Neonate is less than 6 days (≤144 hours) of age at the time of first dose.~* Neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator.~* Neonate birth weight 2500-4000g inclusive.~* Neonate's parents/guardians expect to be available for the duration of the study, and agree to adhere to all protocol requirements.~* Neonate's parents/guardians have provided written informed consent prior to study-related procedures being performed.~Exclusion Criteria:~* Any medical, psychiatric, or social condition of a parent/guardian that in the opinion of the investigator would prevent the neonate's parents/guardians from giving proper informed consent or from complying with the study protocol.~* Neonates with known or suspected major congenital malformations or genetically determined disease.~* Neonates with intussusception.~* Neonates with a known or suspected bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.~* Neonates who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product during the course of the study is anticipated.~* Neonates in whom Essential Programme Immunisation (EPI) vaccines or components are contraindicated.~* Neonates who have received or who expect to receive during the study period, any rotavirus vaccine other than those which will be administered as part of this study.~* Neonates who have ever received, or who are anticipated to receive during the study period, any investigational agent other than those which will be administered as part of this study.~* Neonates with a previous anaphylactic reaction to any drug, vaccine or vaccine component.~* Neonates with a significant evolving neurological disorder.~* Neonates whose parents/guardians are site team employees with direct involvement with the investigators, or who are working on the study.~* Neonates who have been exposed to immunosuppressive courses of glucocorticosteroids, cytotoxic drugs or blood products through prenatal exposure and/or breast milk in the four weeks prior to randomization.~* Neonates with diarrhoea or vomiting in the 24 hours preceding randomisation.~* Neonates with any moderate or severe illness, and/or who have a temperature of ≥37.5˚C axillary/oral or ≥38˚C rectal/tympanic within the 48 hours preceding randomization.

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: 18 Weeks
- Healthy Volunteers: t

Study Arms:
- High dose RV3-BB neonatal schedule (Type: EXPERIMENTAL): High dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
- Mid dose RV3-BB neonatal schedule (Type: EXPERIMENTAL): Mid dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
- Low dose RV3-BB neonatal schedule (Type: EXPERIMENTAL): Low dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
- High dose RV3-BB infant schedule (Type: EXPERIMENTAL): High dose infant RV3-BB vaccine schedule. Placebo for Investigational product dose 1 (0-5 days) and RV3-BB Vaccine for Investigational product doses 2 (week 6) 3 (week 10) and dose 4 (week 14)

Based on this trial design, predict the completion outcome and termination type (if applicable).